Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

• Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards
• Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals
• Validated system provides reliable, consistent carbon footprint data for clients

INCHEON, South Korea, Feb. 6, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming alignment with globally recognized standards.

The validation confirms that Samsung Biologics' PCF calculation methodology complies with global standards, including ISO 14067 and PAS 2050. This reflects the company's advanced and systematically developed approach to carbon accounting across biopharmaceutical manufacturing processes, supporting transparency and consistency in sustainability reporting.

The validation was conducted by DNV, an independent assurance and risk management provider headquartered in Norway. DNV assessed the validity of the company's PCF system across data input, conversion, and output, confirming that the assumptions, methods, and overall approach follow globally accepted practices.

Through this validated PCF framework, Samsung Biologics aims to support clearer communication and greater comparability of product-level carbon footprint data across the biopharmaceutical value chain, in line with evolving client expectations and sustainability requirements.

"Achieving independent validation of our PCF system reflects the rigor and transparency of the carbon data we provide to clients," said John Rim, President and CEO of Samsung Biologics. "This represents the company's continued focus on building sustainable operations based on established standards, while maintaining reliable and consistent manufacturing. As sustainability considerations continue to shape decision-making across the biopharmaceutical industry, we believe this system enables constructive collaboration with our partners."

Samsung Biologics' sustainability efforts have also been recognized through its recent EcoVadis assessment, where the company received a Platinum rating, placing it among the top one percent of companies evaluated globally for sustainability management.

For more information on Samsung Biologics' sustainability efforts, please visit the company's website.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 from the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S. upon deal closure at the end of Q1 2026, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health.

For more information, visit https://samsungbiologics.com/.

Media Contact

Claire Kim, Senior Director [email protected]

Becky Lee, Director [email protected]

SOURCE Samsung Biologics